Merck KGaA is developing matuzumab, a fully humanized epidermal growth factor 
receptor (EGFR)-specific monoclonal antibody, as a potential treatment for 
EGFR-bearing tumors. Matuzumab is currently undergoing phase II clinical trials 
for gastric, cervical, pancreatic and ovarian cancers.